Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Sabry M. Attia; Mohammed A. Al-Hamamah; Moureq R. Alotaibi; Abdullah F. Alasmari; Mohamed S.M. Attia; Sheikh F. Ahmad; Mohamed A. Mahmoud; Ahmed Nadeem; Mushtaq A. Ansari; Saleh A. Bakheet

doi:10.1016/j.mrgentox.2023.503635

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Sabry M. Attia^*, Mohammed A. Al-Hamamah, Moureq R. Alotaibi, Abdullah F. Alasmari, Mohamed S.M. Attia, Sheikh F. Ahmad, Mohamed A. Mahmoud, Ahmed Nadeem, Mushtaq A. Ansari, Saleh A. Bakheet

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

Original language	English
Article number	503635
Journal	Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Volume	888
DOIs	https://doi.org/10.1016/j.mrgentox.2023.503635
State	Published - 1 May 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023 Elsevier B.V.

Keywords

8-OHdG
Aneugenicity
Anti-CD20
Clastogenicity
Inflammation
Oxidative DNA damage

ASJC Scopus subject areas

Genetics
Health, Toxicology and Mutagenesis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mrgentox.2023.503635

Cite this

Attia, S. M., Al-Hamamah, M. A., Alotaibi, M. R., Alasmari, A. F., Attia, M. S. M., Ahmad, S. F., Mahmoud, M. A., Nadeem, A., Ansari, M. A., & Bakheet, S. A. (2023). Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 888, Article 503635. https://doi.org/10.1016/j.mrgentox.2023.503635

@article{e7cf49ffbf8945babd16690ae7b1c713,

title = "Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody",

abstract = "Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.",

keywords = "8-OHdG, Aneugenicity, Anti-CD20, Clastogenicity, Inflammation, Oxidative DNA damage",

author = "Attia, \{Sabry M.\} and Al-Hamamah, \{Mohammed A.\} and Alotaibi, \{Moureq R.\} and Alasmari, \{Abdullah F.\} and Attia, \{Mohamed S.M.\} and Ahmad, \{Sheikh F.\} and Mahmoud, \{Mohamed A.\} and Ahmed Nadeem and Ansari, \{Mushtaq A.\} and Bakheet, \{Saleh A.\}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = may,

day = "1",

doi = "10.1016/j.mrgentox.2023.503635",

language = "English",

volume = "888",

journal = "Mutation Research - Genetic Toxicology and Environmental Mutagenesis",

issn = "1383-5718",

publisher = "Elsevier B.V.",

}

Attia, SM, Al-Hamamah, MA, Alotaibi, MR, Alasmari, AF, Attia, MSM, Ahmad, SF, Mahmoud, MA, Nadeem, A, Ansari, MA & Bakheet, SA 2023, 'Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody', Mutation Research - Genetic Toxicology and Environmental Mutagenesis, vol. 888, 503635. https://doi.org/10.1016/j.mrgentox.2023.503635

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody. / Attia, Sabry M.; Al-Hamamah, Mohammed A.; Alotaibi, Moureq R. et al.
In: Mutation Research - Genetic Toxicology and Environmental Mutagenesis, Vol. 888, 503635, 01.05.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

AU - Attia, Sabry M.

AU - Al-Hamamah, Mohammed A.

AU - Alotaibi, Moureq R.

AU - Alasmari, Abdullah F.

AU - Attia, Mohamed S.M.

AU - Ahmad, Sheikh F.

AU - Mahmoud, Mohamed A.

AU - Nadeem, Ahmed

AU - Ansari, Mushtaq A.

AU - Bakheet, Saleh A.

PY - 2023/5/1

Y1 - 2023/5/1

N2 - Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

AB - Rheumatoid arthritis (RA), an autoimmune disorder in which the immune system attacks healthy cells, is associated with elevated risk of lymphoma. Rituximab, a treatment for non-Hodgkin's lymphoma, has been approved as a treatment for RA. We studied the effects of rituximab on chromosomal stability in collagen-induced arthritis DBA/1J animal models. Micronucleus levels were increased in the mouse models, mainly due to chromosome loss, as detected by fluorescence in situ hybridization; rituximab-treated arthritic mice had significantly less micronucleus formation. Serum 8-hydroxydeoxyguanosine, a DNA oxidative stress marker, was increased in the mice models but reduced following rituximab administration.

KW - 8-OHdG

KW - Aneugenicity

KW - Anti-CD20

KW - Clastogenicity

KW - Inflammation

KW - Oxidative DNA damage

UR - https://www.scopus.com/pages/publications/85151546881

U2 - 10.1016/j.mrgentox.2023.503635

DO - 10.1016/j.mrgentox.2023.503635

M3 - Article

C2 - 37188433

AN - SCOPUS:85151546881

SN - 1383-5718

VL - 888

JO - Mutation Research - Genetic Toxicology and Environmental Mutagenesis

JF - Mutation Research - Genetic Toxicology and Environmental Mutagenesis

M1 - 503635

ER -

Aneugenic and clastogenic alterations in the DBA/IJ mouse model of rheumatoid arthritis treated with rituximab, an anti-CD20 antibody

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this